ReviewOncogene2006
MicroRNAs and chromosomal abnormalities in cancer cells.
Review in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 264 citations in OpenAlex.
- Chemopreventive Effects of Lycopene in miR-21 Knockout and Wild-Type Pancreatic Cancer Cells.Scientifica · 2026Article
- Current updates regarding biogenesis, functions and dysregulation of microRNAs in cancer: Innovative approaches for detection using CRISPR/Cas13‑based platforms (Review).International journal of molecular medicine · 2025Review
- Exploring the Role of miRNA-101a in the Circulatory System's Adaptive Mechanisms in Hypertensive Disorders of Pregnancy.Diagnostics (Basel, Switzerland) · 2025Article
- hsa-mir-483-3p modulates delayed breast cancer recurrence.Scientific reports · 2025Article
- Unraveling the Regulatory Role of HuR/microRNA Axis in Colorectal Cancer Tumorigenesis.Cancers · 2024Review
- Non-Coding RNAs and Innate Immune Responses in Cancer.Biomedicines · 2024Review
- Review
- Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.Molecular biology reports · 2022Review
- The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives.Cancers · 2022Review
- MicroRNA Profile of Human Small Intestinal Tumors Compared to Colorectal Tumors.Journal of clinical medicine · 2022Article
- miRNA therapeutics in precision oncology: a natural premium to nurture.Exploration of targeted anti-tumor therapy · 2022Review
- Arsenic-induced epigenetic changes in cancer development.Seminars in cancer biology · 2021Review
- Ultrasound-Based Method for the Identification of Novel MicroRNA Biomarkers in Prostate Cancer.Genes · 2021Article
- Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment.Current medical science · 2021Review
- Plant-derived xenomiRs and cancer: Cross-kingdom gene regulation.Saudi journal of biological sciences · 2021Review
- Review
- Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.International journal of molecular sciences · 2021Review
- The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.International journal of molecular sciences · 2020Review
- Curcumin Regulates the r(CGG)Frontiers in neuroscience · 2020Article
- MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells facilitating the identification of cancer-associated protein coding oncogenes and tumor suppressors. The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome resulted in the discovery that microRNA (miRNA) genes, encoding for a class of small noncoding RNAs, frequently resides in such genomic regions. The combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contribute to downregulation or overexpression of miRNAs. The consequent abnormal expression of miRNAs affect cell cycle, survival and differentiation programs and selective targeting of these noncoding genes could provide novel therapeutic options for killing the malignant cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.